Earlier start to high-efficacy MS drugs cuts 10-year disability
Australian-led research adds to evidence questioning the escalation approach to therapy
A decade after diagnosis, people with multiple sclerosis who started high-efficacy immunotherapy in the first two years have less disability than late-starters of such therapies, according to Australian-led research.
University of Melbourne researchers and international colleagues examined data on 213 people with relapsing-remitting MS from two registries who started therapy with rituximab, ocrelizumab, mitoxantrone, alemtuzumab or natalizumab within two years of their diagnosis.